GoodRx (NASDAQ:GDRX) Shares Gap Down - Here's Why

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report)'s share price gapped down prior to trading on Friday . The stock had previously closed at $4.95, but opened at $4.81. GoodRx shares last traded at $4.81, with a volume of 131,259 shares traded.

Wall Street Analyst Weigh In

GDRX has been the subject of a number of research analyst reports. Barclays dropped their price target on GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a research report on Monday, November 11th. Morgan Stanley cut their price target on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a report on Tuesday, December 17th. Citigroup lowered their price objective on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a report on Friday, January 10th. KeyCorp lowered their target price on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Finally, Mizuho began coverage on GoodRx in a report on Wednesday, December 4th. They issued a "neutral" rating and a $5.00 target price for the company. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $8.38.

GoodRx Stock Performance

The firm has a market cap of $1.84 billion, a price-to-earnings ratio of -160.67, a P/E/G ratio of 2.41 and a beta of 1.28. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The business's 50-day simple moving average is $4.65 and its two-hundred day simple moving average is $6.18.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. nVerses Capital LLC purchased a new stake in shares of GoodRx in the 3rd quarter valued at approximately $33,000. EP Wealth Advisors LLC purchased a new position in shares of GoodRx during the third quarter worth approximately $73,000. Sanctuary Advisors LLC purchased a new stake in GoodRx during the 3rd quarter valued at approximately $85,000. Sugar Maple Asset Management LLC purchased a new position in GoodRx during the 4th quarter worth $122,000. Finally, Olympiad Research LP purchased a new position in shares of GoodRx during the 4th quarter worth approximately $147,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.